Complete Overview of Diabetes Drugs Including Off-Label Weight Loss Use | Research

The takeaway

Comprehensive review covers traditional and new-generation diabetes medications including GLP-1 drugs, with focus on their growing off-label use for weight loss.

Traditional to new-gen
Complete review spanning insulin to GLP-1 drugs, including off-label weight loss applications

What the researchers found

Comprehensive review of traditional and new-generation diabetes agents documents expanding off-label weight loss use driven by GLP-1 RA efficacy and the growing overlap between diabetes and obesity treatment.

Why it matters

Many patients use diabetes drugs off-label for weight loss. Understanding the evidence and risks across all medication classes helps guide safe prescribing.

How the study worked

Narrative review of diabetes medications including traditional agents, new-generation therapies, and off-label weight management applications.

What this study cannot tell us

Narrative review — not a systematic analysis. Off-label use evidence is less rigorous than approved-indication data.

How to read the evidence

Narrative review — comprehensive overview but not a quantitative evidence synthesis.

When this study was published

Published in 2026; covers the latest diabetes medication landscape.

The bigger picture

The line between diabetes and obesity medication is disappearing as drugs like semaglutide and tirzepatide receive dual indications, reshaping pharmaceutical categories.

Questions still open

Should more diabetes drugs be formally approved for weight loss?
What are the risks of using diabetes medications off-label in non-diabetic patients?

Common questions

Can diabetes drugs be used just for weight loss?

Some diabetes medications like semaglutide (Wegovy) and tirzepatide (Zepbound) are now FDA-approved specifically for weight loss. Others are used off-label, meaning doctors prescribe them for weight loss even though that's not their approved indication.

What are the newest diabetes medications?

The newest classes include GLP-1 receptor agonists (semaglutide, liraglutide), dual GIP/GLP-1 agonists (tirzepatide), and triple agonists (retatrutide, in trials). These offer superior weight loss and cardiovascular benefits over older drugs.

Read the original research

Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 87551225261422610

View on PubMed ↗Publisher’s paper ↗

Citation

Castellana, Eleonora; Budau, Patricia Madalina; Chiappetta, Maria Rachele. (2026). Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 87551225261422610. https://doi.org/10.1177/87551225261422610